Evidence map›Paper›PMID 31892658›Full record

ArticleBMJ open2019

Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view.

Laura Folgori, Irja Lutsar, Joseph F Standing, A Sarah Walker, Emmanuel Roilides, Theoklis E Zaoutis, Hasan Jafri, Carlo Giaquinto, Mark A Turner, Mike Sharland

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Antibiotics needed to treat multidrug-resistant infections in neonates.Bulletin of the World Health Organization · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 9 countries.

Laura FolgoriPaediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George's University of London, London, UK lfolgori@sgul.ac.uk.ORCID 0000-0002-0680-0450
Irja LutsarDepartment of Microbiology, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Joseph F StandingPaediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George's University of London, London, UK.
A Sarah WalkerNuffield Department of Clinical Medicine; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
Emmanuel RoilidesInfectious Diseases Unit, 3rd Department of Paediatrics, Faculty of Medicine, Aristotle University 96 School of Health Sciences, Thessaloniki, Greece.
Theoklis E ZaoutisDivision of Infectious Diseases and the Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Hasan JafriAstraZeneca, 950 Wind River Ln, Gaithersburg, MD, USA.
Carlo GiaquintoDepartment of Woman's and Child's Health, University of Padova, Padua, Italy.
Mark A TurnerInstitute of Translational Medicine, Centre for Women's Health Research, Liverpool Women's Hospital, Crown Street, Liverpool, UK.
Mike SharlandPaediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George's University of London, London, UK.
St George's, University of London · GBAristotle University of Thessaloniki · GRAstraZeneca (Netherlands) · NLChildren's Hospital of Philadelphia · USUniversity of Liverpool · GBUniversity of Oxford · GBUniversity of Padua · ITUniversity of Tartu · EE

Funding

Medical Research Council MC_UU_12023/22Medical Research Council MR/M008665/1
6 · The paper itself

Abstract

Antimicrobial development for children remains challenging due to multiple barriers to conducting randomised clinical trials (CTs). There is currently considerable heterogeneity in the design and conduct of paediatric antibiotic studies, hampering comparison and meta-analytic approaches. The board of the European networks for paediatric research at the European Medicines Agency (EMA), in collaboration with the Paediatric European Network for Treatments of AIDS-Infectious Diseases network (www.penta-id.org), recently developed a Working Group on paediatric antibiotic CT design, involving academic, regulatory and industry representatives. The evidence base for any specific criteria for the design and conduct of efficacy and safety antibiotic trials for children is very limited and will evolve over time as further studies are conducted. The suggestions being put forward here are based on the adult EMA guidance, adapted for neonates and children. In particular, this document provides suggested guidance on the general principles of harmonisation between regulatory and strategic trials, including (1) standardised key inclusion/exclusion criteria and widely applicable outcome measures for specific clinical infectious syndromes (CIS) to be used in CTs on efficacy of antibiotic in children; (2) key components of safety that should be reported in paediatric antibiotic CTs; (3) standardised sample sizes for safety studies. Summarising views from a range of key stakeholders, specific criteria for the design and conduct of efficacy and safety antibiotic trials in specific CIS for children have been suggested. The recommended criteria are intended to be applicable to both regulatory and clinical investigator-led strategic trials and could be the basis for harmonisation in the design and conduct of CTs on antibiotics in children. The next step is further discussion internationally with investigators, paediatric CTs networks and regulators.

Indexed as

Clinical Trials as TopicNeonatologyPediatricsAnti-Bacterial AgentsBacterial InfectionsChildDrug Resistance, MicrobialEndpoint DeterminationHumansInfant, NewbornInternational CooperationReference StandardsResearch DesignAnti-Bacterial Agentsantibioticsclinical trialspaediatrics

Identifiers

PMID31892658
PMCPMC6955510
OpenAlexW2998394273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.